Al-Sawaf, O., Stumpf, J., Zhang, C., Simon, F., Albareda, F. B., Feyzi, E., Ghia, P., Gregor, M., Kater, A., Lindström, V., Mattsson, M., Niemann, C., Staber, P., Tadmor, T., Thornton, P., Wendtner, C., Janssens, A., Noesslinger, T., Bohn, J., Cunha-Bang, C. D., Poulsen, C., Ranti, J., Illmer, T., Schoettker, B., Böttcher, S., Gaska, T., Vandenberghe, E., Clifford, R., Benjamini, O., Frustaci, A., Scarfò, L., Sportoletti, P., Schreurs, J., Levin, M., Straaten, H. V. D., Klift, M. V. D., Tran, H., Serna, J. D. L., Loscertales, J., Lindblad, O., Sandstedt, A. B., Goede, J., Baumann, M., Fink, A. M., Fischer, K., Ritgen, M., Kreuzer, K., Schneider, C., Tausch, E., Stilgenbauer, S., Robrecht, S., Eichhorst, B., Hallek, M. (2025). Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial. Blood. https://doi.org/10.1182/blood-2025-1